Addressing Challenges in TP53-Mutant Acute Myeloid Leukemia

Commentary
Video

Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.

Eunice S. Wang, MD, spoke with CancerNetwork® at the 2024 European Hematology Association (EHA) Congress about ongoing challenges in the acute myeloid leukemia (AML) field, particularly those related to managing TP53-mutated disease.

According to Wang, chief of the Leukemia Service of the Department of Medicine at Roswell Park Comprehensive Cancer Center in Buffalo, New York, targeting TP53-mutant AML with immunotherapy is still a challenge in the field following presentations on data related to treatments such as the anti-CD47 agent magrolimab. Data presented at the meeting showed that treatment regimens including magrolimab plus azacitidine did not meet the primary end points among patients with myelodysplastic syndrome in the phase 3 ENHANCE study (NCT04313881)1 and among those with AML in the phase 3 ENHANCE-3 study (NCT05079230).2

Wang stated that future meetings may help address whether immunotherapies, bispecific agents, or CAR T-cell therapies can impact the AML treatment paradigm.

Transcript:

TP53 still remains a challenge [in AML]. We’ve been somewhat disappointed. We’ve been excited every year or so only to be disappointed. [Regarding] the data out there, I don’t see anything that’s particularly targeting TP53 mutations [in] patients. Immunotherapy also remains a challenge. We had thought that because most of our conventional chemotherapy agents don’t work that we would see some impact of immunotherapeutics in TP53-mutant AML. For example, the recent failure of magrolimab being presented at this EHA meeting with the results of the ENHANCE trials, which are a great database for the efficacy of an [azacitidine combination] but didn’t show any improvement in an [azacitidine combination] with magrolimab, particularly in patients with TP53-mutant disease. That still remains a challenge, and we’ll need to be looking forward to future meetings as to how that’s being addressed and whether immunotherapeutic agents, bispecifics, and CAR T-cell therapy have yet to influence our treatment paradigms as of now for this difficult-to-treat myeloid malignancy.

References

  1. Sallman D, Garcia-Manero G, Daver N, et al. Magrolimab (Magro) + azacitidine (AZA) vs placebo (PBO) + AZA in patients (PTs) with untreated higher-risk (HR) myelodysplastic syndromes (MDS): phase 3 ENHANCE study final analysis. Presented at the 2024 European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain. Abstract S181.
  2. Daver N, Vyas P, Huls G, et al. Magrolimab vs placebo in combination with venetoclax and azacitidine in previously untreated patients with acute myeloid leukemia who are ineligible for intensive chemotherapy: the ENHANCE-3 study. Presented at the 2024 European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain. Abstract S138.
Recent Videos
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Osimertinib/chemotherapy and amivantamab/lazertinib have exhibited an efficacy advantage vs osimertinib in patients with EGFR-mutant NSCLC.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Related Content